Table 2.
Clinical course in the first year after diagnosis for patients followed by nephrology (group 2). Categorical variables are expressed as frequency (percentage), and continuous variables are expressed as median [IQR]
| Time to first nephrology visit (days) | 0.0 [0.0, 29.0] |
| Kidney biopsy | 166 (14.6) |
| Seen by GI | 155 (13.6) |
| Seen by rheumatology | 301 (26.4) |
| Treatment | |
| Observation | 647 (56.8) |
| RAAS blockade alone | 69 (6.1) |
| RAAS blockade overall | 187 (16.4) |
| Systemic Corticosteroids (all) | 414 (36.3) |
| Enteral corticosteroids | 400 (35.1) |
| IV corticosteroids | 137 (12.0) |
| Systemic corticosteroids > 1 prescription | 316 (27.7) |
| Immunosuppressive medication | 90 (7.9) |
| Azathioprine | 48 (4.2) |
| Cyclophosphamide | 8 (0.7) |
| Calcineurin inhibitor (CNI) | 6 (0.5) |
| Mycophenolate (MMF) | 38 (3.3) |
| Rituximab | 3 (0.3) |
| Hypertension diagnosis | 244 (21.4) |
| Treated with RAAS blocker | 187 (16.4) |
| Treated with other antihypertensive | 107 (9.4) |
| Calcium channel blocker | 73 (6.4) |
| Beta blocker | 16 (1.4) |
| Diuretic (loop and thiazide) | 54 (4.7) |
| Other antihypertensive medication | 54 (4.7) |
GI, gastroenterology; RAAS, renin–angiotensin–aldosterone system; IV, intravenous